About Finch Therapeutics
Finch Therapeutics is a publicly listed company based in Somerville (United States) founded in 2004 by Tom Borody, Zain Kassam, and Jared James Burgess. It operates as a microbiome-based therapies are developed via human-first discovery platform. Finch Therapeutics has raised $184 million across 5 funding rounds from investors including Susquehanna, Octave Group and Symbiosis. The company has 1 employees. Finch Therapeutics offers products and services including Microbiome Assets and IP Estate. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is Finch Therapeutics Group, Inc. Its competitors include Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Finch Therapeutics was founded in 2004 and is based in Somerville, United States. Microbiome-based therapies are developed using a human-first discovery platform, supported by proprietary machine learning for a clinically annotated library of strains linked to clinical phenotypes. An AquaShell technology is employed for targeted delivery of microbial therapeutics. Focus is placed on Inflammatory Bowel Disease in preclinical stages, along with other applications in the biotechnology sector.
- Headquarters Somerville, United States
- Employees 1
- Founders Tom Borody, Zain Kassam, Jared James Burgess
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website finchtherapeutics.com
- Social LinkedIn X
- Legal Name Finch Therapeutics Group, Inc.
- Net Profit-$13.88 M (USD)81.44as on Dec 31, 2024
- EBITDA-$18.68 M (USD)42.48as on Dec 31, 2024
- Total Equity Funding$184M (USD)
in 5 rounds
- Latest Funding Round$90M (USD), Series D
Sep 2020
- InvestorsSusquehanna
& 13 more
- Employee Count1
Products & Services of Finch Therapeutics
Finch Therapeutics offers a comprehensive portfolio of products and services, including Microbiome Assets and IP Estate.
Portfolio for microbiome-based treatments targeting diseases
Collection of patents for microbiome innovations and applications
Funding Insights of Finch Therapeutics
Finch Therapeutics has successfully raised a total of $184M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $90 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $184M
- Total Rounds 5
- Last Round Series D — $90M
- First Round $800,000
(Dec 2015)
- Investors Count 14
All 5 funding rounds of Finch Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $90M | Series D | – | – | |
| Jul 2019 | $53.47M | Series C | – | – | |
| Mar 2018 | $36M | Series B | – | Shumway Capital, Willett Advisors | – |
| Jan 2017 | $3.73M | Series A | – | – | – |
| Dec 2015 | $800,000 | Seed | – | – | – |
14 investors in total: 14 institutional.
Investors in Finch Therapeutics
Finch Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Susquehanna, Octave Group and Symbiosis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in transformative biotech companies by OMX Ventures. | – | omx.vc | Lincolnshire, USA | |
Diversified alternative assets are managed by the investment firm. | – | msdpartners.com | New York, United States | |
Private equity single family office | – | msdcapital.com | New York, United States | |
Early-stage companies in science and technology are supported by Humboldt Fund. | 2020 | humboldtfund.com | - | |
Provider of a PE and VC investing firm | – | shumwaycapital.com | Greenwich, United States | |
Philanthropic assets are managed by Willett Advisors LLC. | – | willettadvisors.com | New York, United States | |
Venture capital investments are provided by OCV Partners. | – | ocvpartners.com | Los Angeles, United States | |
Growth equity investments are made by the private equity firm. | – | avenirgrowth.com | New York, United States | |
Diversified investment management is handled by SIG across multiple assets. | 1987 | sig.com | Bala Cynwyd, United States | |
A venture capital fund is operated to invest in technology companies. | – | tptf.co | Taipei, Taiwan |
Investor details for Finch Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Finch Therapeutics
12 people are tracked at Finch Therapeutics (5 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Tom Borody | Co-Founder | Leadership |
Zain Kassam | Co-Founder | Leadership |
Jared James Burgess | Co-Founder | Leadership |
Howard Franklin | Chief Medical Officer | Leadership |
Matthew P. Blischak | CEO | Leadership |
Susan E. Graf | Director | Board & advisors |
Christian Lange | Director | Board & advisors |
Chris Shumway | Director | Board & advisors |
Domenic Ferrante | Director | Board & advisors |
Eliza Zalis | Scientist II | Team |
Milord Athis | Lab Technician | Team |
Sara Bither | Senior Manager of Laboratory Operations | Team |
Complete people profiles for Finch Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Finch Therapeutics
Finch Therapeutics is a publicly listed company on the OTC with ticker symbol FNCH in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Mar 2021
- Listed onNASDAQ: FNCH
- Listed entityFinch Therapeutics Group, Inc.
- Exchange sectorHealth services
- ISINUS31773D2009
- Share price$7.30 (-39.17% on the day) · 2026-03-24
- Market capitalisation$11.7M
- Volume (last session)128,123
- Analyst consensusNo rating
Financials of Finch Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | – | -$13.9M | -$18.7M |
| 2023 | $107,000 | -$74.8M | -$32.5M |
| 2022 | $861,000 | -$114.7M | -$89.6M |
| 2021 | $18.5M | -$58.2M | -$57.7M |
Detailed financial statements for Finch Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Finch Therapeutics
4 dated milestones of Finch Therapeutics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Finch Therapeutics is founded.
- Funding First funding round of $800K.
- Funding Latest funding round, Series D, of $90.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Finch Therapeutics
Finch Therapeutics has 9 listed competitors in our database, 9 of them funded. They include Insitro, BridgeBio, Adaptive Biotechnologies, Moderna and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes |
Detailed competitors of Finch Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Finch Therapeutics
The website of Finch Therapeutics (finchtherapeutics.com) receives about 2.9K visits a month and ranks #6,039,653 among all websites worldwide, #6,382 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▲ 1.2% vs previous month
- Unique visitors1.2K
per month
- Global rank#6,039,653
among all websites
- Category rank#6,382
Health · Biotechnology and Pharmaceuticals
- Bounce rate58%
- Pages per visit1.6
- Average visit24 sec
- DevicesDesktop 14% · Mobile 86%
Websites whose visitors overlap most with Finch Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
westorg.org | westorg.org | 100% | – | #5,528,792 | – |
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as Finch Therapeutics (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Finch Therapeutics
Complete news archive for Finch Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Finch Therapeutics
Finch Therapeutics was founded in 2004 and raised its 1st funding round 11 years after it was founded.
Finch Therapeutics is headquartered in Somerville, United States. It is registered at Somerville, Massachusetts, United States.
Finch Therapeutics is a funded company, having raised a total of $184M across 5 funding rounds to date. The company's 1st funding round was a Seed of $800K, raised on Dec 2015.
Finch Therapeutics has 1 employees.
Finch Therapeutics was founded in 2004 and is based in Somerville, United States. Microbiome-based therapies are developed using a human-first discovery platform, supported by proprietary machine learning for a clinically annotated library of strains linked to clinical phenotypes. An AquaShell technology is employed for targeted delivery of microbial therapeutics. Focus is placed on Inflammatory Bowel Disease in preclinical stages, along with other applications in the biotechnology sector.
Finch Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Finch Therapeutics offers Microbiome Assets and IP Estate.
Yes, Finch Therapeutics is publicly traded on OTC under the ticker symbol FNCH.
Finch Therapeutics has 14 investors. Key investors include Susquehanna, Octave Group, Symbiosis, OMX Ventures, and MSD Partners.
Finch Therapeutics operates through Finch Therapeutics Group, Inc..